P

    Pacira BioSciences, Inc. (PCRX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $25.90
    +0.14 (+0.54%)

    Market Cap: $1.03B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    70%(28/40)
    Avg Surprise
    +55.06%
    Streak
    2 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$0.71
    Range$0.50 - $0.82
    7 analysts
    EPS Revisions
    1
    0
    7d
    1
    1
    30d
    EPS Estimate Drift
    90d ago$0.77+7.6%
    60d ago$0.76+6.6%
    30d ago$0.76+6.6%
    7d ago$0.77+7.9%
    Current$0.71
    Revenue Consensus
    $182M
    Range$177M - $187M
    6 analysts
    Dec 31, 2026
    EPS Consensus$0.96
    Range$0.79 - $1.07
    7 analysts
    Revenue Consensus
    $207M
    Range$202M - $213M
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.96---
    Sep 26EST
    		-$0.71---
    Jun 26
    		$0.44$0.27+62.96%Beat-40.5%
    Mar 26
    		$0.60$0.56+7.14%Beat-3.2%
    Dec 25
    		$0.32$0.60-46.67%Miss-64.8%
    Sep 25
    		$0.70$0.65+7.69%Beat-11.4%
    Jun 25
    		$0.74$0.71+4.23%Beat-16.9%
    Mar 25
    		$0.62$0.60+3.33%Beat+0.0%
    Dec 24
    		$0.91$0.83+9.60%Beat+2.2%
    Sep 24
    		$0.79$0.70+12.86%Beat+9.7%
    Jun 24
    		$0.89$0.70+27.14%Beat+14.1%
    Mar 24
    		$0.62$0.62+0.00%Beat+17.0%
    Dec 23
    		$0.89$0.87+2.30%Beat+11.2%
    Sep 23
    		$0.72$0.78-7.69%Miss+12.5%
    Jun 23
    		$0.78$0.76+2.63%Beat+52.9%
    Mar 23
    		$0.53$0.62-14.52%Miss-17.2%
    Dec 22
    		$0.80$0.83-3.61%Miss-17.5%
    Sep 22
    		$0.64$0.76-15.79%Miss-11.1%
    Jun 22
    		$0.51$0.85-40.00%Miss-33.8%
    Mar 22
    		$0.64$0.83-22.89%Miss+20.8%
    Dec 21
    		$0.97$0.90+7.78%Beat+11.5%
    Sep 21
    		$0.72$0.65+10.77%Beat+5.9%
    Jun 21
    		$0.77$0.74+4.05%Beat+541.7%
    Mar 21
    		$0.53$0.63-15.87%Miss+0.0%
    Dec 20
    		$0.87$0.81+7.41%Beat+55.4%
    Sep 20
    		$0.68$0.65+4.62%Beat+41.7%
    Jun 20
    		$0.12$0.09+33.33%Beat-70.7%
    Mar 20
    		$0.53$0.30+76.67%Beat+140.9%
    Dec 19
    		$0.56$0.44+27.27%Beat+19.1%
    Sep 19
    		$0.48$0.33+45.45%Beat+54.8%
    Jun 19
    		$0.41$0.34+20.59%Beat+70.8%
    Mar 19
    		$0.22$0.26-15.38%Miss+1000.0%
    Dec 18
    		$0.47$0.28+67.86%Beat+23.7%
    Sep 18
    		$0.31$0.08+287.50%Beat+181.8%
    Jun 18
    		$0.24$0.07+242.86%Beat+318.2%
    Mar 18
    		$0.02$0.03-33.33%Miss+110.5%
    Dec 17
    		$0.38$0.10+280.00%Beat+322.2%
    Sep 17
    		$0.11$-0.07+257.14%Beat-45.0%
    Jun 17
    		$-0.11$-0.05-120.00%Miss-
    Mar 17
    		$-0.19$-0.04-375.00%Miss-
    Dec 16
    		$0.09$0.01+800.00%Beat-
    Sep 16
    		$0.20$-0.04+600.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio12.57EV/EBITDA10.26x
    Price/FCF5.69xFCF Yield17.56%
    Profitability
    Profit Margin1.96%Operating Margin6.17%
    ROE2.05%ROIC1.56%
    Financial Health
    Debt/Equity0.54xInterest Coverage1.18x
    Current Ratio5.04xQuick Ratio3.94x
    Trading Statistics
    Beta0.27Avg Volume665.52K
    52-Week High$27.6652-Week Low$18.80

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$25.06
    SMA 20$24.78
    SMA 50$25.20
    SMA 200$23.77
    EMA 10$25.27
    EMA 20$25.10
    EMA 50$24.90
    EMA 200$24.16

    MACD

    Line: 0.13Signal: -0.08Hist: 0.21

    ADX

    ADX: 20.7+DI: 22.2-DI: 17.0

    Aroon & PSAR

    Aroon Up24.0
    Aroon Down56.0
    PSAR$23.39

    Bollinger Bands

    Upper Band$27.08
    Lower Band$22.48
    %B Position1857%(Upper)
    Band Width0.74

    RSI (14-Day)

    Neutral
    57.6

    Momentum Oscillators

    Stoch %K93.3
    Stoch %D93.8
    Williams %R-5.2
    ROC (10d)11.4%
    Momentum2.66
    CCI (20d)81.4
    MFI (14d)57.8

    Volatility Measures

    ATR (14d)$0.83(3.2%)
    StdDev (20d)1.15
    Hist Vol48.7%(High)

    Volume Flow

    VWAP$25.81
    OBV10.2M
    AD Line2.9M
    CMF (20d)-0.025

    Volume Metrics

    Avg Vol (20d)640.5K
    Vol Ratio0.6x
    VWMA (20d)$24.83

    Pivot Points

    R3$26.51
    R2$26.28
    R1$26.02
    Pivot Point$25.79
    S1$25.53
    S2$25.30
    S3$25.04

    Advanced Oscillators

    TSI3.45
    Ultimate Osc68.2
    KST-32.81

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$192.40M$177.38M$196.87M$179.52M$181.10M$168.92M$187.25M$168.57M$178.02M$167.12M$181.24M$163.93M
    Cost of Revenue$44.16M$36.41M$40.30M$34.28M$40.87M$34.31M$39.89M$38.86M$44.26M$47.42M$47.69M$39.75M
    Gross Profit$148.24M$140.96M$156.57M$145.24M$140.23M$134.62M$147.37M$129.71M$133.76M$119.70M$133.55M$124.18M
    Operating Expenses$143.97M$134.06M$154.23M$138.88M$131.73M$132.63M$122.66M$269.24M$105.52M$106.49M$100.38M$106.45M
    R&D$30.24M$28.07M$37.80M$25.97M$28.20M$25.34M$23.90M$19.10M$20.34M$18.24M$19.46M$20.83M
    SG&A$91.81M$93.94M$101.61M$91.80M$88.58M$86.78M$79.61M$74.33M$68.13M$72.03M$65.80M$67.95M
    Operating Income$4.27M$6.90M$2.34M$6.36M$8.50M$1.99M$24.70M$-139,527,000$28.24M$13.21M$33.17M$17.72M
    Interest Income$1.94M$1.93M$2.29M$8.53M$5.01M$6.89M$5.55M$5.48M$4.75M$3.90M$3.42M$2.77M
    Interest Expense$3.62M$3.70M$3.89M$5.26M$4.70M$4.58M$4.68M$4.69M$-3,634,000$3.32M$3.39M$3.46M
    Income Before Tax$2.56M$5.00M$571,000$9.52M$-1,927,000$8.71M$25.53M$-138,856,000$36.58M$13.64M$33.72M$16.60M
    Income Tax Expense$-2,098,000$2.08M$-1,066,000$4.09M$2.92M$3.89M$9.48M$4.61M$17.70M$4.66M$8.85M$5.74M
    Net Income$4.65M$2.92M$1.64M$5.43M$-4,847,000$4.81M$16.04M$-143,466,000$18.89M$8.98M$24.87M$10.86M
    EBITDA$26.41M$28.11M$19.16M$28.13M$24.61M$26.52M$39.34M$-118,533,000$47.85M$32.18M$48.30M$36.44M
    EBIT$4.23M$6.77M$2.17M$6.25M$-2,240,000$6.39M$24.65M$-139,649,000$28.20M$13.05M$33.68M$17.30M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PCRX

    News

    ETFs Investing in Pacira Biosciences, Inc. Stocks

    This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold Pacira Biosciences, Inc. stocks. The list is sorted by market value and includes various details such as weight, issuer, management style, focus, expense ratio, AUM, price, change percentage, relative volume, and 3-year NAV total return for each ETF. This information helps investors identify diversified opportunities with potentially lower risk.

    TradingView•8/22/26•
    Neutral

    Rice Hall James & Associates LLC Purchases Shares of 93,396 Pacira BioSciences, Inc. $PCRX

    Rice Hall James & Associates LLC recently acquired 93,396 shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) during the second quarter, valued at approximately $2.37 million, representing about 0.23% of the company. Other institutional investors have also adjusted their holdings, while company insiders have sold shares. Pacira BioSciences reported strong earnings, beating analyst estimates, and has received a consensus "Hold" rating from Wall Street analysts with an average target price of $30.20.

    MarketBeat•8/19/26•
    Neutral

    Pacira BioSciences (NASDAQ:PCRX) Insider Jonathan Slonin Sells 3,040 Shares of Stock

    Pacira BioSciences insider Jonathan Slonin sold 3,040 shares of the company's stock for a total of $70,619.20. This transaction reduced his ownership by 1.39% to 216,384 shares and was executed under a pre-arranged Rule 10b5-1 trading plan. The company's stock traded up 3.3% to $24.00, and it recently beat EPS estimates with a revenue increase of 6.2% year-over-year.

    MarketBeat•8/18/26•
    Neutral

    Pacira BioSciences (PCRX) CMO sells 3,040 shares in 10b5-1 plan

    Pacira BioSciences (PCRX) Chief Medical Officer, Jonathan Slonin, sold 3,040 shares of common stock on August 17, 2026, at $23.23 per share through an open-market transaction. This sale was conducted under a Rule 10b5-1 trading plan adopted on August 12, 2025. Following the transaction, Slonin directly holds 216,383.646 shares, which includes shares acquired via the company’s employee stock purchase plan.

    Stock Titan•8/18/26•
    Somewhat-Bearish

    Pacira BioSciences (NASDAQ: PCRX) faces $70.6K share sale in 2026

    Pacira BioSciences (NASDAQ: PCRX) is set to see a proposed sale of 3,040 common shares with an aggregate market value of $70,619.20 on August 17, 2026. The sale, detailed in a Form 144 SEC filing, will be executed through Fidelity Brokerage Services LLC on the NASDAQ market. The shares were originally acquired by the filer through an Employee Stock Purchase Plan and restricted stock vesting in mid-2022.

    Stock Titan•8/17/26•
    Neutral

    Frequently Asked Questions About PCRX

    Does PCRX pay dividends?
    Pacira BioSciences, Inc. (PCRX) does not currently pay a regular dividend.
    What is PCRX's P/E ratio?
    Pacira BioSciences, Inc. has a price-to-earnings (P/E) ratio of 12.57.
    What is PCRX's market cap?
    Pacira BioSciences, Inc. (PCRX) has a market capitalization of $1.03B with a current stock price of $25.90.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In